Revolutionizing Diabetes and Obesity Care
The global rise in Type 2 diabetes and obesity has spurred a growing demand for innovative health solutions, particularly GLP-1, GGG, and GIPR agonists. Our Forecast projections indicate that the GLP-1 market could reach $70 billion by 2030, underscoring the need for innovative supply and manufacturing solutions. Despite the MENA region's GLP-1 market featuring lower-end pricing, it remains attractive due to high diabetes and obesity prevalence, with Saudi Arabia securing a significant 35% market share. Currently, there are 105 products in the pipeline for GLP-1, GGG, GIPR agonists, with companies like Novo Nordisk, Zealand Pharma, Eli Lilly and Company, and Gmax Bio pharm leading the way in substantial pipelines for these health solutions.
Revolutionizing Drug Development: The Impact of AI and Data Science in Pharma
Mar, 2024
This blog delves into the integration of AI technologies like machine learning and natural language processing in pharmaceutical processes, spotlighting their role in accelerating drug discovery, optimizing clinical trials, and personalizing patient care.
Driving Innovation in Drug Manufacturing: The Next Frontier for Pharma Companies
Apr, 2024
This blog post explores the latest trends and technologies revolutionizing drug production, from continuous manufacturing to AI integration.
Pharma Portfolio Management: Strategies for Success
Sep, 2023
Optimize your pharmaceutical portfolio management strategy for success in the dynamic industry with our expert insights on Pharma Portfolio Management.